Gastrointestinal Cancer | Specialty

Dr. Wu on Possible Combinations With TAS-102 in CRC

December 23rd 2015

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses potential combinations with TAS-102 for the treatment of patients with colorectal cancer.

Dr. John Marshall on Steps to Finding a Cure for Colorectal Cancer

December 21st 2015

John Marshall, MD, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses curing colorectal cancer.

Contemporary Evidence-Based Management of Newly Diagnosed Metastatic Colorectal Cancer

December 17th 2015

Contemporary efforts toward defining molecular subsets of colorectal cancer can potentially aid our ability to refine therapy and improve outcomes for patients with colorectal cancer.

Dr. Jennifer Wu on Immunotherapy in Mismatch Repair Deficient CRC

December 4th 2015

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the potential for immunotherapy in colorectal cancer with mismatch repair deficiency.

Dr. John Marshall on the Importance of Molecular Profiling in Colorectal Cancer

November 10th 2015

John Marshall, MD, Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses the importance of molecular testing in colorectal cancer.

Dr. Wu on Efficacy of Approved Agents in Colorectal Cancer

November 4th 2015

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the efficacy of regorafenib and TAS-102 for the treatment of patients with colorectal cancer.

Nanotechnology May Lead to Tumor-Priming Strategy in Pancreatic Cancer

November 3rd 2015

Researchers from United States and Ireland have formed a partnership to advance nanoparticle-based delivery systems that would not only drive sustained-release of cytotoxic agents, but also could improve penetration of these treatments within the tumor and allow them to continue working for days or weeks.

Pembrolizumab Granted Breakthrough Status for Microsatellite Instability-High mCRC

November 2nd 2015

The FDA has granted a breakthrough therapy designation to pembrolizumab as a potential therapy for patients with microsatellite instability-high metastatic colorectal cancer.

Metastatic Colorectal Cancer: Expert Perspectives on Improving Care

October 30th 2015

Multidisciplinary Care in Advanced Colorectal Cancer

October 30th 2015

Treating Refractory Colorectal Cancer

October 30th 2015

The Genetics of Metastatic Colorectal Cancer

October 30th 2015

FDA Approves Second-Line MM-398 Regimen for Metastatic Pancreatic Cancer

October 22nd 2015

The FDA has approved MM-398 (irinotecan liposome injection; Onivyde) in combination with 5-fluorouracil (5-FU) and leucovorin as a treatment for patients with metastatic pancreatic cancer following prior administration of a gemcitabine-based regimen.

Everolimus Shows Robust Activity in Lung/GI NETs

October 17th 2015

Everolimus improved progression-free survival by 7.1 months compared with placebo in patients with lung/gastrointestinal (GI) neuroendocrine tumors, representing a 52% reduction in the risk of progression or death.

The Limitations of VEGF Inhibition in Colorectal Cancer

October 14th 2015

Leonard Saltz, MD, discusses antiangiogenesis and the use of VEGF inhibitors in colorectal cancer.

ASCO Releases Provisional Recommendation for RAS Testing in mCRC

October 10th 2015

ASCO has recommended extended RAS testing as a predictive biomarker of response for anti-EGFR monoclonal antibodies, further stressing the importance of broader molecular analyses for patients with metastatic colorectal cancer.

Radiofrequency Ablation Dwell Time Significantly Impacts Survival in HCC

September 30th 2015

Overall survival was improved by more than 25 months when lyso-thermosensitive liposomal doxorubicin was administered with optimized (≥45 minutes dwell time) radiofrequency ablation in patients with hepatocellular carcinoma.

Dr. Philippe Ruszniewski on NETTER-1 Study Results

September 26th 2015

Philippe Ruszniewski, MD, Professor of Gastroenterology, Chief of Division of Gastroenterology and Pancreatology, University of Paris VII, Beaujon Hospital, discusses the results of the phase 3 NETTER-1 study.

Everolimus May Be New Standard of Care in Advanced Lung, GI NETs

September 26th 2015

Treatment with everolimus was associated with a 52% improvement in median progression-free survival compared with placebo in patients with advanced lung and gastrointestinal neuroendocrine tumors.

FDA Approves TAS-102, New Nivolumab Breakthrough Designation, Two Priority Reviews, and More

September 25th 2015